Taro Pharmaceutical Industries (NYSE:TARO) Downgraded by StockNews.com

Posted by on May 3rd, 2023

Taro Pharmaceutical Industries (NYSE:TARO – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

Separately, HC Wainwright reduced their price target on Taro Pharmaceutical Industries from $54.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, January 25th.

Taro Pharmaceutical Industries Stock Performance

Taro Pharmaceutical Industries stock opened at $25.75 on Wednesday. Taro Pharmaceutical Industries has a 52 week low of $22.89 and a 52 week high of $40.15. The stock has a market capitalization of $967.69 million, a P/E ratio of 21.11 and a beta of 0.63. The stock has a 50-day simple moving average of $26.49 and a 200 day simple moving average of $28.69.

Institutional Investors Weigh In On Taro Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Taro Pharmaceutical Industries by 73.4% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,184 shares of the company’s stock worth $29,000 after acquiring an additional 501 shares during the period. UBS Group AG boosted its stake in shares of Taro Pharmaceutical Industries by 71.6% in the second quarter. UBS Group AG now owns 925 shares of the company’s stock valued at $34,000 after buying an additional 386 shares during the period. Quadrant Capital Group LLC boosted its stake in shares of Taro Pharmaceutical Industries by 154.5% in the third quarter. Quadrant Capital Group LLC now owns 1,275 shares of the company’s stock valued at $38,000 after buying an additional 774 shares during the period. Signaturefd LLC boosted its stake in shares of Taro Pharmaceutical Industries by 270.1% in the third quarter. Signaturefd LLC now owns 1,373 shares of the company’s stock valued at $41,000 after buying an additional 1,002 shares during the period. Finally, Y.D. More Investments Ltd bought a new stake in shares of Taro Pharmaceutical Industries in the fourth quarter valued at approximately $50,000. Institutional investors own 11.45% of the company’s stock.

Taro Pharmaceutical Industries Company Profile

(Get Rating)

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories.

Featured Articles

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.